State of Alaska Department of Revenue Reduces Holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART)

State of Alaska Department of Revenue lessened its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 30.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 91,264 shares of the life sciences company's stock after selling 40,127 shares during the quarter. State of Alaska Department of Revenue owned about 0.12% of Integra LifeSciences worth $2,006,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in IART. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Integra LifeSciences during the 1st quarter worth $251,000. Assenagon Asset Management S.A. boosted its stake in Integra LifeSciences by 2,418.7% during the first quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock worth $39,581,000 after buying an additional 1,728,480 shares during the period. Handelsbanken Fonder AB boosted its stake in Integra LifeSciences by 22.5% during the first quarter. Handelsbanken Fonder AB now owns 28,902 shares of the life sciences company's stock worth $636,000 after buying an additional 5,300 shares during the period. GAMMA Investing LLC increased its position in shares of Integra LifeSciences by 3,595.1% during the first quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock valued at $5,140,000 after acquiring an additional 22,721 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Integra LifeSciences in the 4th quarter valued at approximately $1,721,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

Integra LifeSciences stock remained flat at $11.87 during trading on Wednesday. 1,415,809 shares of the company were exchanged, compared to its average volume of 1,004,090. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.72 and a current ratio of 1.21. Integra LifeSciences Holdings Corporation has a one year low of $11.06 and a one year high of $32.66. The stock has a market capitalization of $922.42 million, a PE ratio of -31.24, a PEG ratio of 0.66 and a beta of 1.16. The firm has a 50-day moving average of $13.62 and a 200 day moving average of $19.55.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The firm had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. During the same quarter in the previous year, the firm posted $0.55 EPS. The business's revenue for the quarter was up 3.7% on a year-over-year basis. On average, equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IART. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. JPMorgan Chase & Co. cut their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Wells Fargo & Company decreased their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. JMP Securities dropped their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Finally, Truist Financial reduced their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Integra LifeSciences currently has an average rating of "Hold" and a consensus target price of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.